Oak Asset Management LLC Has $3.23 Million Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Oak Asset Management LLC reduced its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,085 shares of the medical equipment provider’s stock after selling 180 shares during the quarter. Intuitive Surgical accounts for 1.2% of Oak Asset Management LLC’s holdings, making the stock its 28th biggest holding. Oak Asset Management LLC’s holdings in Intuitive Surgical were worth $3,227,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Intuitive Surgical by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after purchasing an additional 196,316 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after buying an additional 272,741 shares in the last quarter. Edgewood Management LLC boosted its stake in Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after buying an additional 374,667 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Intuitive Surgical by 2.0% in the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after buying an additional 88,977 shares in the last quarter. Finally, Norges Bank acquired a new stake in Intuitive Surgical in the fourth quarter valued at about $1,313,238,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on ISRG shares. Stifel Nicolaus raised their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. The Goldman Sachs Group started coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective on the stock. BTIG Research raised their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Citigroup lifted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Robert W. Baird cut their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday, April 19th. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $403.67.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $444.85 on Monday. The company has a market cap of $157.79 billion, a P/E ratio of 80.30, a PEG ratio of 5.75 and a beta of 1.39. The stock has a 50 day simple moving average of $403.83 and a two-hundred day simple moving average of $383.50. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $447.11.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.00 earnings per share. On average, research analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the sale, the senior vice president now owns 883 shares in the company, valued at $343,628.28. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,956 shares of company stock worth $6,927,011. 0.80% of the stock is owned by corporate insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.